Immuneering Corporation — Income Charts
4 years of history · ending 2023-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$0
Cost of Revenue
$0
Gross Profit
$0
R&D
$42M
D&A
$323K
Operating Income
$-58M
EBITDA
$-58M
Interest Income
$4M
Other Income/Expense
$217K
Pretax Income
$-51M
Tax Provision
$-307K
Net Income
$-53M
Gross Margin
50.1%
Operating Margin
-16325.8%
Net Margin
-15937.3%
Effective Tax Rate
0.9%
Deferred Tax Assets
$390K
Deferred Tax Liabilities
$113K
DTA Valuation Allowance
$43M
Tax Credit Carryforwards
$6M
NOL Carryforwards
$19M
ETR (Continuing Operations)
0.0%
ETR Federal Statutory
21.0%
ETR State + Local (pp)
-3.2%
Operating Lease Cost
$877K
Revenue YoY Variation
-100.0%
Income YoY Variation
-12.9%